NCT06011954Recruiting
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer. People in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed PADCEV Injection and other medicines to treat their cancer. People in the study will be treated according to their clinic's standard practice. This study is about collecting information only. This study will survey people who know they are receiving PADCEV Injection. The aims of the study are to check outcomes of treatment with PADCEV and record any medical problems during the study. Once a doctor has prescribed PADCEV Injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. During this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. If a person in the study stops taking PADCEV Injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of PADCEV Injection or until they start a different medicine for their cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 228 (estimated)
- First submitted
- 22 Aug 2023
- Start date
- 1 Nov 2023
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Astellas Pharma Korea, Inc.
- Diseases
- Bladder cancer, Childhood cancers
- NCT number
- NCT06011954
What you commit to
- Study type: Observational
- Planned participants: 228
- From 1 Nov 2023 to the primary completion date, 31 Jul 2027
- 18 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with any contraindication for PADCEV Injection, according to the approved local label.
- Patients who receive or are going to receive any investigational medicine during the observation period.
Who the study is looking for
- Patients who receive treatment with PADCEV Injection, according to the approved local label.
Sex: All · Does not accept healthy volunteers
Sites (18)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.